Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus

Semiz, Sabina; Dujić, Tanja; Ostanek, Barbara; Prnjavorac, Besim; Bego, Tamer; Malenica, Maja; Marc, Janja; Čaušević, Adlija

doi:10.17305/bjbms.2010.2662

Cited by 23 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the CYP2C19 gene polymorphism, only one study on the association between CYP2C19 and hypertension showed that CYP2C19*2 variants did not have any association with hypertension in a Korean population (Shin et al, 2012). Concerning diabetes mellitus, CYP2C9*2, *3, and CYP2C19*2 have been shown to have no association with diabetes mellitus (Semiz et al, 2010;Weise et al, 2010), which is consistent with our results. One study even showed that individuals with the CYP2C19*2 variant seem to protect against metabolic syndrome (Gaio et al, 2014).…”

Section: Discussionsupporting

confidence: 90%

Association of CYP2C19*2 with hyperlipidemia in patients with the wild-type CYP2C9

Khalighi¹,

Cheng²,

Mirabbasi³

et al. 2017

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Arachidonic acids are metabolized by cytochromes P450 (CYP450) to epoxyeicosatrienoic acids (EETs). EETs have many cardiovascular protective effects such as vasodilation, anti-hypertension, anti-inflammation, lipid-lowering effects, and favorable effects on glucose homeostasis. This study aimed to investigate whether gene polymorphism of cytochrome P450 CYP2C9 and CYP2C19 are related to the risk of hypertension, hyperlipidemia, and diabetes mellitus. Four hundred and eighty patients were enrolled, and single nucleotide polymorphisms for CYP2C9 and CYP2C19 were genotyped. The percentages of patients with hypertension, hyperlipidemia, and diabetes mellitus with CYP2C9 *1/*2, *1/*3, and wild-type (CYP2C9 *1/*1) were similar, and the chi-square (χ 2 ) analysis showed no statistically significant differences between each genotype. Further, no statistically significant differences were observed for the percentages of patients with hypertension, hyperlipidemia, and diabetes mellitus between CYP2C19 genotypes. Subgroup analysis showed that among patients with the wild-type CYP2C9 genotype (CYP2C9*1/*1, N = 297), patients with CYP2C19*1/*2 and *2/*2 genotypes have a significantly higher percentage of hyperlipidemia than those with CYP2C19 *1/*1, *1/*17, and *17/*17 genotypes. Binary logistic regression analysis also suggested that among patients with the wild-type CYP2C9 genotype, the CYP2C19*2 allele was associated with risk of hyperlipidemia (P = 0.027, odds ratio = 2.036; 95% confidence interval = 1.09-3.82). General linear model analysis showed that among our general research population, both CYP2C9 and CYP2C19 had no effect on hyperlipidemia independently, but the interaction between CYP2C9 and CYP2C19 and hyperlipidemia was statistically significant (F = 2.682, P = 0.031). Our study suggests that the association of CYP2C19*2 with hyperlipidemia was specific among patients with the wild-type CYP2C9.

show abstract

Section: Discussionsupporting

confidence: 90%

Association of CYP2C19*2 with hyperlipidemia in patients with the wild-type CYP2C9

Khalighi¹,

Cheng²,

Mirabbasi³

et al. 2017

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Similarly, Semiz et al38 reported that no significant difference in allele frequencies for CYP2C9 * 2 , was demonstrated between diabetic and non-diabetic subjects. Recently, Kaur-Knudsen et al39 reported the findings of large studies on the association between genetic variation in CYP 1B1 and CYP2C9 and the risk of disease, and rebutted the hypotheses that these genetic variants?influenced the risk of tobacco-related cancer, female cancer (as cervical and endometrial cancers), chronic obstructive pulmonary disease, and ischemic vascular disease.…”

Section: Discussionmentioning

confidence: 92%

Association ofCYP2C9Genetic Variants with Vitiligo

et al. 2014

View full text Add to dashboard Cite

BackgroundVitiligo is a depigmenting skin disorder in which genetic factors play an important role.ObjectiveTo examine the association of CYP2C9 *1/*2/*3 gene polymorphism with vitiligo.MethodsIn this case controlled study, 95 Saudi patients with vitiligo (50 men and 45 women), with a mean age of 27.3 years, were analyzed. Patients were compared to 86 healthy controls from the same locality (76 men and 10 women), with a mean age of 20.1 years. In all participants, DNA was extracted and processed for characterization of 2C9 *1/*2/*3 gene variants using real time-polymerase chain reaction.ResultsVitiligo patients have a significantly higher CYP2C9 *3 allele carriage rate compared to controls (32.7% versus 4.7%, p=0.00, odds ratio=9.9, 95% confidence interval=3.3~29.6). On the other hand, frequencies of CYP2C9 *2 genotypes and alleles did not show any significant difference between vitiligo cases and controls. When the frequencies of CYP2C9 genotypes were compared among subgroups of age, gender, family history, and disease patterns, the cases with positive consanguinity had significantly higher frequencies of homozygous genotypes than others (p=0.029).ConclusionCYP2C9 *3 allele carriage is probably associated with vitiligo susceptibility.

show abstract

“…Significant interethnic differences in the distribution of allele frequencies rs776746*G and rs776746*A was observed (Table 3) [6,21,25,36,[44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63]. The rs776746*G allele is common in European popula tions and less common in Asian populations, and a significantly lower number of cases was observed in black populations.…”

Section: Resultsmentioning

confidence: 99%

CYP2D6, CYP3A5, and CYP3A4 gene polymorphisms in Russian, Tatar, and Bashkir populations

et al. 2015

View full text Add to dashboard Cite

The allele and genotype frequency distribution at polymorphic loci rs3892097 (184G>A) of CYP2D6 gene, rs776746 (6986A>G) of the CYP3A5 gene and rs2740574 (-392A>G) of the CYP3A4 gene in Russians, Tatars, and Bashkirs was examined. Samples were taken from residents of Bashkortostan Republic (1240 men and women aged from 20 to 109 years and consisted of 443 Russians, 517 Tatars, and 280 Bash kirs). Allele identification was conducted using PCR RFLP or PCR with TaqMan probes. The "nonfunc tional" allele rs3892097*A of the CYP2D6 gene was detected in populations of Russians, Tatars, and Bashkirs in 17.2, 9.5, and 7.1% cases, respectively.The rs776746*G allele of the CYP3A5 gene encoding the CYP3A5 isoenzyme with decreased activity was revealed with a frequency of 94.6% in populations of Russians, 94.3% in the Tatar population, and 91.5% in the Bashkir population. The share of the minor allele rs2740574*G of the CYP3A4 was 4.0% in populations of Russians, 0.5% in the Tatar population, and 0.9% in the Bashkir pop ulation. It has been previously shown that the rs3892097*A, rs776746*G, and rs2740574*G allele frequencies vary significantly in different world populations. Since allele variants of CYP2D6, CYP3A5, and CYP3A4 genes can play essential role in interindividual and in interethnic differences in the metabolism of many therapeutic agents, the obtained results could be used in the prognosis of pharmacotherapy efficacy in populations of Russians, Tatars, and Bashkirs.

show abstract

Analysis of CYP2C92, CYP2C192, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus

Cited by 23 publications

References 7 publications

Association of CYP2C19*2 with hyperlipidemia in patients with the wild-type CYP2C9

Association of CYP2C19*2 with hyperlipidemia in patients with the wild-type CYP2C9

Association ofCYP2C9Genetic Variants with Vitiligo

CYP2D6, CYP3A5, and CYP3A4 gene polymorphisms in Russian, Tatar, and Bashkir populations

Contact Info

Product

Resources

About